Evolution of Metastases in Space and Time under Immune Selection.

Autor:	Angelova M; INSERM, Laboratory of Integrative Cancer Immunology, Sorbonne Université, Sorbonne Paris Cité, Université Paris Descartes, Université Paris Diderot, Centre de Recherche des Cordeliers, 75006 Paris, France., Mlecnik B; INSERM, Laboratory of Integrative Cancer Immunology, Sorbonne Université, Sorbonne Paris Cité, Université Paris Descartes, Université Paris Diderot, Centre de Recherche des Cordeliers, 75006 Paris, France; Inovarion, Paris, France., Vasaturo A; INSERM, Laboratory of Integrative Cancer Immunology, Sorbonne Université, Sorbonne Paris Cité, Université Paris Descartes, Université Paris Diderot, Centre de Recherche des Cordeliers, 75006 Paris, France., Bindea G; INSERM, Laboratory of Integrative Cancer Immunology, Sorbonne Université, Sorbonne Paris Cité, Université Paris Descartes, Université Paris Diderot, Centre de Recherche des Cordeliers, 75006 Paris, France., Fredriksen T; INSERM, Laboratory of Integrative Cancer Immunology, Sorbonne Université, Sorbonne Paris Cité, Université Paris Descartes, Université Paris Diderot, Centre de Recherche des Cordeliers, 75006 Paris, France., Lafontaine L; INSERM, Laboratory of Integrative Cancer Immunology, Sorbonne Université, Sorbonne Paris Cité, Université Paris Descartes, Université Paris Diderot, Centre de Recherche des Cordeliers, 75006 Paris, France., Buttard B; INSERM, Laboratory of Integrative Cancer Immunology, Sorbonne Université, Sorbonne Paris Cité, Université Paris Descartes, Université Paris Diderot, Centre de Recherche des Cordeliers, 75006 Paris, France., Morgand E; INSERM, Laboratory of Integrative Cancer Immunology, Sorbonne Université, Sorbonne Paris Cité, Université Paris Descartes, Université Paris Diderot, Centre de Recherche des Cordeliers, 75006 Paris, France., Bruni D; INSERM, Laboratory of Integrative Cancer Immunology, Sorbonne Université, Sorbonne Paris Cité, Université Paris Descartes, Université Paris Diderot, Centre de Recherche des Cordeliers, 75006 Paris, France., Jouret-Mourin A; Institut Roi Albert II, Department of Medical Oncology Cliniques universitaires St-Luc and Institut de Recherche Clinique et Experimentale (Pole MIRO), Université Catholique de Louvain, 1348 Brussels, Belgium., Hubert C; Institut Roi Albert II, Department of Medical Oncology Cliniques universitaires St-Luc and Institut de Recherche Clinique et Experimentale (Pole MIRO), Université Catholique de Louvain, 1348 Brussels, Belgium., Kartheuser A; Institut Roi Albert II, Department of Medical Oncology Cliniques universitaires St-Luc and Institut de Recherche Clinique et Experimentale (Pole MIRO), Université Catholique de Louvain, 1348 Brussels, Belgium., Humblet Y; Institut Roi Albert II, Department of Medical Oncology Cliniques universitaires St-Luc and Institut de Recherche Clinique et Experimentale (Pole MIRO), Université Catholique de Louvain, 1348 Brussels, Belgium., Ceccarelli M; Department of Science and Technology, Università degli Studi del Sannio, 82100, Benevento, Italy; BIOGEM Istituto di Ricerche Genetiche 'G. Salvatore,' I-83031 Ariano Irpino, Italy., Syed N; Biomedical Informatics Division, Sidra Medicine, Doha, Qatar., Marincola FM; Refuge Biotechnologies Inc., Menlo Park, CA 94025, USA; Office of the Chief Research Officer, Sidra Medicine, 26999 Doha, Qatar., Bedognetti D; Tumor Biology, Immunology, and Therapy Section, Sidra Medicine, 26999 Doha, Qatar., Van den Eynde M; INSERM, Laboratory of Integrative Cancer Immunology, Sorbonne Université, Sorbonne Paris Cité, Université Paris Descartes, Université Paris Diderot, Centre de Recherche des Cordeliers, 75006 Paris, France; Institut Roi Albert II, Department of Medical Oncology Cliniques universitaires St-Luc and Institut de Recherche Clinique et Experimentale (Pole MIRO), Université Catholique de Louvain, 1348 Brussels, Belgium., Galon J; INSERM, Laboratory of Integrative Cancer Immunology, Sorbonne Université, Sorbonne Paris Cité, Université Paris Descartes, Université Paris Diderot, Centre de Recherche des Cordeliers, 75006 Paris, France. Electronic address: jerome.galon@crc.jussieu.fr.
Jazyk:	angličtina
Zdroj:	Cell [Cell] 2018 Oct 18; Vol. 175 (3), pp. 751-765.e16. Date of Electronic Publication: 2018 Oct 11.
DOI:	10.1016/j.cell.2018.09.018
Abstrakt:	We examined how the immune microenvironment molds tumor evolution at different metastatic organs in a longitudinal dataset of colorectal cancer. Through multiplexed analyses, we showed that clonal evolution patterns during metastatic progression depend on the immune contexture at the metastatic site. Genetic evidence of neoantigen depletion was observed in the sites with high Immunoscore and spatial proximity between Ki67 + tumor cells and CD3 + cells. The immunoedited tumor clones were eliminated and did not recur, while progressing clones were immune privileged, despite the presence of tumor-infiltrating lymphocytes. Characterization of immune-privileged metastases revealed tumor-intrinsic and tumor-extrinsic mechanisms of escape. The lowest recurrence risk was associated with high Immunoscore, occurrence of immunoediting, and low tumor burden. We propose a parallel selection model of metastatic progression, where branched evolution could be traced back to immune-escaping clones. The findings could inform the understanding of cancer dissemination and the development of immunotherapeutics. (Copyright © 2018 Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu